Skip to main content
Top
Published in: Journal of General Internal Medicine 1/2021

01-01-2021 | Prostate Cancer | Original Research

Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network

Authors: Anand Shah, MD, MBA, Thomas J. Polascik, MD, Daniel J. George, MD, John Anderson, MD, MPH, Terry Hyslop, PhD, Alicia M. Ellis, PhD, Andrew J. Armstrong, MD, MSc, Michael Ferrandino, MD, Glenn M. Preminger, MD, Rajan T. Gupta, MD, W. Robert Lee, MD, MS, Nadine J. Barrett, PhD, John Ragsdale, MD, Coleman Mills, MA, CCRP, Devon K. Check, PhD, Alireza Aminsharifi, MD, Ariel Schulman, MD, Christina Sze, MD, MS, Efrat Tsivian, MD, Kae Jack Tay, MD, Steven Patierno, PhD, Kevin C. Oeffinger, MD, Kevin Shah, MD, MBA

Published in: Journal of General Internal Medicine | Issue 1/2021

Login to get access

Abstract

Background

Implementation methods of risk-stratified cancer screening guidance throughout a health care system remains understudied.

Objective

Conduct a preliminary analysis of the implementation of a risk-stratified prostate cancer screening algorithm in a single health care system.

Design

Comparison of men seen pre-implementation (2/1/2016–2/1/2017) vs. post-implementation (2/2/2017–2/21/2018).

Participants

Men, aged 40–75 years, without a history of prostate cancer, who were seen by a primary care provider.

Interventions

The algorithm was integrated into two components in the electronic health record (EHR): in Health Maintenance as a personalized screening reminder and in tailored messages to providers that accompanied prostate-specific antigen (PSA) results.

Main Measures

Primary outcomes: percent of men who met screening algorithm criteria; percent of men with a PSA result. Logistic repeated measures mixed models were used to test for differences in the proportion of individuals that met screening criteria in the pre- and post-implementation periods with age, race, family history, and PSA level included as covariates.

Key Results

During the pre- and post-implementation periods, 49,053 and 49,980 men, respectively, were seen across 26 clinics (20.6% African American). The proportion of men who met screening algorithm criteria increased from 49.3% (pre-implementation) to 68.0% (post-implementation) (p < 0.001); this increase was observed across all races, age groups, and primary care clinics. Importantly, the percent of men who had a PSA did not change: 55.3% pre-implementation, 55.0% post-implementation. The adjusted odds of meeting algorithm-based screening was 6.5-times higher in the post-implementation period than in the pre-implementation period (95% confidence interval, 5.97 to 7.05).

Conclusions

In this preliminary analysis, following implementation of an EHR-based algorithm, we observed a rapid change in practice with an increase in screening in higher-risk groups balanced with a decrease in screening in low-risk groups. Future efforts will evaluate costs and downstream outcomes of this strategy.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69:7-34, 2019CrossRef Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. CA Cancer J Clin 69:7-34, 2019CrossRef
3.
go back to reference Schroder FH, Hugosson J, Roobol MJ, et al: Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384:2027-35, 2014CrossRef Schroder FH, Hugosson J, Roobol MJ, et al: Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384:2027-35, 2014CrossRef
4.
go back to reference Fenton JJ, Weyrich MS, Durbin S, et al: Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 319:1914-1931, 2018CrossRef Fenton JJ, Weyrich MS, Durbin S, et al: Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 319:1914-1931, 2018CrossRef
5.
go back to reference Gomella LG, Liu XS, Trabulsi EJ, et al: Screening for prostate cancer: the current evidence and guidelines controversy. Can J Urol 18:5875-83, 2011PubMed Gomella LG, Liu XS, Trabulsi EJ, et al: Screening for prostate cancer: the current evidence and guidelines controversy. Can J Urol 18:5875-83, 2011PubMed
6.
go back to reference Burns RB, Olumi AF, Owens DK, et al: Would You Recommend Prostate-Specific Antigen Screening for This Patient?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med 170:770-778, 2019CrossRef Burns RB, Olumi AF, Owens DK, et al: Would You Recommend Prostate-Specific Antigen Screening for This Patient?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Ann Intern Med 170:770-778, 2019CrossRef
7.
go back to reference Welch HG, Black WC: Overdiagnosis in cancer. J Natl Cancer Inst 102:605-13, 2010CrossRef Welch HG, Black WC: Overdiagnosis in cancer. J Natl Cancer Inst 102:605-13, 2010CrossRef
8.
go back to reference Moyer VA, Force USPST: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157:120-34, 2012CrossRef Moyer VA, Force USPST: Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157:120-34, 2012CrossRef
9.
go back to reference Smith RA, Manassaram-Baptiste D, Brooks D, et al: Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 64:30-51, 2014CrossRef Smith RA, Manassaram-Baptiste D, Brooks D, et al: Cancer screening in the United States, 2014: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 64:30-51, 2014CrossRef
10.
go back to reference Mohler JL, Kantoff PW, Armstrong AJ, et al: Prostate cancer, version 2.2014. J Natl Compr Cancer Netw 12:686-718, 2014CrossRef Mohler JL, Kantoff PW, Armstrong AJ, et al: Prostate cancer, version 2.2014. J Natl Compr Cancer Netw 12:686-718, 2014CrossRef
11.
go back to reference Jemal A, Fedewa SA, Ma J, et al: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. JAMA 314:2054-61, 2015CrossRef Jemal A, Fedewa SA, Ma J, et al: Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations. JAMA 314:2054-61, 2015CrossRef
12.
go back to reference Houston KA, King J, Li J, et al: Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013. J Urol 199:676-682, 2018CrossRef Houston KA, King J, Li J, et al: Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013. J Urol 199:676-682, 2018CrossRef
13.
go back to reference Pinsky PF, Prorok PC, Kramer BS: Prostate Cancer Screening - A Perspective on the Current State of the Evidence. N Engl J Med 376:1285-1289, 2017CrossRef Pinsky PF, Prorok PC, Kramer BS: Prostate Cancer Screening - A Perspective on the Current State of the Evidence. N Engl J Med 376:1285-1289, 2017CrossRef
14.
go back to reference Pinsky PF, Prorok PC, Yu K, et al: Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 123:592-599, 2017CrossRef Pinsky PF, Prorok PC, Yu K, et al: Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 123:592-599, 2017CrossRef
15.
go back to reference Force USPST, Grossman DC, Curry SJ, et al: Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 319:1901-1913, 2018CrossRef Force USPST, Grossman DC, Curry SJ, et al: Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 319:1901-1913, 2018CrossRef
16.
go back to reference Andriole GL, Crawford ED, Grubb RL, 3rd, et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-9, 2009CrossRef Andriole GL, Crawford ED, Grubb RL, 3rd, et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-9, 2009CrossRef
17.
go back to reference DeSantis CE, Miller KD, Goding Sauer A, et al: Cancer statistics for African Americans, 2019. CA Cancer J Clin 69:211-233, 2019CrossRef DeSantis CE, Miller KD, Goding Sauer A, et al: Cancer statistics for African Americans, 2019. CA Cancer J Clin 69:211-233, 2019CrossRef
18.
go back to reference Smith RA, Andrews KS, Brooks D, et al: Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 68:297-316, 2018CrossRef Smith RA, Andrews KS, Brooks D, et al: Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 68:297-316, 2018CrossRef
19.
go back to reference Mohler JL, Antonarakis ES, Armstrong AJ, et al: Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 17:479-505, 2019CrossRef Mohler JL, Antonarakis ES, Armstrong AJ, et al: Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 17:479-505, 2019CrossRef
20.
go back to reference Vickers AJ, Cronin AM, Bjork T, et al: Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 341:c4521, 2010CrossRef Vickers AJ, Cronin AM, Bjork T, et al: Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 341:c4521, 2010CrossRef
21.
go back to reference Vickers AJ, Ulmert D, Sjoberg DD, et al: Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 346:f2023, 2013CrossRef Vickers AJ, Ulmert D, Sjoberg DD, et al: Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. BMJ 346:f2023, 2013CrossRef
22.
go back to reference Preston MA, Batista JL, Wilson KM, et al: Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol 34:2705-11, 2016CrossRef Preston MA, Batista JL, Wilson KM, et al: Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol 34:2705-11, 2016CrossRef
23.
go back to reference Aminsharifi A, Schulman A, Anderson J, et al: Primary care perspective and implementation of a multidisciplinary, institutional prostate cancer screening algorithm embedded in the electronic health record. Urol Oncol 36:502.e1-502.e6, 2018CrossRef Aminsharifi A, Schulman A, Anderson J, et al: Primary care perspective and implementation of a multidisciplinary, institutional prostate cancer screening algorithm embedded in the electronic health record. Urol Oncol 36:502.e1-502.e6, 2018CrossRef
24.
go back to reference Wilt TJ, Brawer MK, Jones KM, et al: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203-13, 2012CrossRef Wilt TJ, Brawer MK, Jones KM, et al: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203-13, 2012CrossRef
25.
go back to reference Wilt TJ, Jones KM, Barry MJ, et al: Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med 377:132-142, 2017CrossRef Wilt TJ, Jones KM, Barry MJ, et al: Follow-up of Prostatectomy versus Observation for Early Prostate Cancer. N Engl J Med 377:132-142, 2017CrossRef
26.
go back to reference Parker CC, James ND, Brawley CD, et al: Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392:2353-2366, 2018CrossRef Parker CC, James ND, Brawley CD, et al: Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392:2353-2366, 2018CrossRef
27.
go back to reference Sydes MR, Spears MR, Mason MD, et al: Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol 29:1235-1248, 2018CrossRef Sydes MR, Spears MR, Mason MD, et al: Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol 29:1235-1248, 2018CrossRef
28.
go back to reference Bill-Axelson A, Holmberg L, Garmo H, et al: Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med 379:2319-2329, 2018CrossRef Bill-Axelson A, Holmberg L, Garmo H, et al: Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med 379:2319-2329, 2018CrossRef
29.
go back to reference Bates D, Machler M, Bolker BM, et al: Fitting Linear Mixed-Effects Models Using lme4. J Stat Softw 67:1-48, 2015CrossRef Bates D, Machler M, Bolker BM, et al: Fitting Linear Mixed-Effects Models Using lme4. J Stat Softw 67:1-48, 2015CrossRef
31.
go back to reference Merlo J, Chaix B, Ohlsson H, et al: A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena. J Epidemiol Community Health 60:290-7, 2006CrossRef Merlo J, Chaix B, Ohlsson H, et al: A brief conceptual tutorial of multilevel analysis in social epidemiology: using measures of clustering in multilevel logistic regression to investigate contextual phenomena. J Epidemiol Community Health 60:290-7, 2006CrossRef
32.
go back to reference Krumholz HM, Radford MJ, Wang Y, et al: National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 280:623-9, 1998CrossRef Krumholz HM, Radford MJ, Wang Y, et al: National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project. JAMA 280:623-9, 1998CrossRef
33.
go back to reference Sial SH, Malone M, Freeman JL, et al: Beta blocker use in the treatment of community hospital patients discharged after myocardial infarction. J Gen Intern Med 9:599-605, 1994CrossRef Sial SH, Malone M, Freeman JL, et al: Beta blocker use in the treatment of community hospital patients discharged after myocardial infarction. J Gen Intern Med 9:599-605, 1994CrossRef
34.
go back to reference Ayanian JZ, Hauptman PJ, Guadagnoli E, et al: Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med 331:1136-42, 1994CrossRef Ayanian JZ, Hauptman PJ, Guadagnoli E, et al: Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med 331:1136-42, 1994CrossRef
35.
go back to reference Grol R, Grimshaw J: From best evidence to best practice: effective implementation of change in patients’ care. Lancet 362:1225-1230, 2003CrossRef Grol R, Grimshaw J: From best evidence to best practice: effective implementation of change in patients’ care. Lancet 362:1225-1230, 2003CrossRef
37.
go back to reference Dowding D, Randell R, Gardner P, et al: Dashboards for improving patient care: review of the literature. Int J Med Inform 84:87-100, 2015CrossRef Dowding D, Randell R, Gardner P, et al: Dashboards for improving patient care: review of the literature. Int J Med Inform 84:87-100, 2015CrossRef
38.
go back to reference Twohig PA, Rivington JR, Gunzler D, et al: Clinician dashboard views and improvement in preventative health outcome measures: a retrospective analysis. BMC Health Serv Res 19:475, 2019CrossRef Twohig PA, Rivington JR, Gunzler D, et al: Clinician dashboard views and improvement in preventative health outcome measures: a retrospective analysis. BMC Health Serv Res 19:475, 2019CrossRef
39.
go back to reference Baron RC, Melillo S, Rimer BK, et al: Intervention to increase recommendation and delivery of screening for breast, cervical, and colorectal cancers by healthcare providers a systematic review of provider reminders. Am J Prev Med 38:110-7, 2010CrossRef Baron RC, Melillo S, Rimer BK, et al: Intervention to increase recommendation and delivery of screening for breast, cervical, and colorectal cancers by healthcare providers a systematic review of provider reminders. Am J Prev Med 38:110-7, 2010CrossRef
40.
go back to reference Jun T, Kwang H, Mou E, et al: An Electronic Best Practice Alert Based on Choosing Wisely Guidelines Reduces Thrombophilia Testing in the Outpatient Setting. J Gen Intern Med 34:29-30, 2019CrossRef Jun T, Kwang H, Mou E, et al: An Electronic Best Practice Alert Based on Choosing Wisely Guidelines Reduces Thrombophilia Testing in the Outpatient Setting. J Gen Intern Med 34:29-30, 2019CrossRef
41.
go back to reference Ancker JS, Edwards A, Nosal S, et al: Effects of workload, work complexity, and repeated alerts on alert fatigue in a clinical decision support system. BMC Med Inform Decis Mak 17:36, 2017CrossRef Ancker JS, Edwards A, Nosal S, et al: Effects of workload, work complexity, and repeated alerts on alert fatigue in a clinical decision support system. BMC Med Inform Decis Mak 17:36, 2017CrossRef
42.
go back to reference Brown B, Young J, Smith DP, et al: A multidisciplinary team-oriented intervention to increase guideline recommended care for high-risk prostate cancer: A stepped-wedge cluster randomised implementation trial. Implement Sci 13(1):43, 2016. https://doi.org/10.1186/s13012-018-0733-x. Brown B, Young J, Smith DP, et al: A multidisciplinary team-oriented intervention to increase guideline recommended care for high-risk prostate cancer: A stepped-wedge cluster randomised implementation trial. Implement Sci 13(1):43, 2016. https://​doi.​org/​10.​1186/​s13012-018-0733-x.
43.
go back to reference Preston MA, Gerke T, Carlsson SV, et al: Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. Eur Urol 75:399-407, 2019CrossRef Preston MA, Gerke T, Carlsson SV, et al: Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. Eur Urol 75:399-407, 2019CrossRef
44.
go back to reference Guise JM, Savitz LA, Friedman CP: Mind the Gap: Putting Evidence into Practice in the Era of Learning Health Systems. J Gen Intern Med 33:2237-2239, 2018CrossRef Guise JM, Savitz LA, Friedman CP: Mind the Gap: Putting Evidence into Practice in the Era of Learning Health Systems. J Gen Intern Med 33:2237-2239, 2018CrossRef
45.
go back to reference Nwaru BI, Friedman C, Halamka J, et al: Can learning health systems help organisations deliver personalised care? BMC Med 15:177, 2017CrossRef Nwaru BI, Friedman C, Halamka J, et al: Can learning health systems help organisations deliver personalised care? BMC Med 15:177, 2017CrossRef
Metadata
Title
Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network
Authors
Anand Shah, MD, MBA
Thomas J. Polascik, MD
Daniel J. George, MD
John Anderson, MD, MPH
Terry Hyslop, PhD
Alicia M. Ellis, PhD
Andrew J. Armstrong, MD, MSc
Michael Ferrandino, MD
Glenn M. Preminger, MD
Rajan T. Gupta, MD
W. Robert Lee, MD, MS
Nadine J. Barrett, PhD
John Ragsdale, MD
Coleman Mills, MA, CCRP
Devon K. Check, PhD
Alireza Aminsharifi, MD
Ariel Schulman, MD
Christina Sze, MD, MS
Efrat Tsivian, MD
Kae Jack Tay, MD
Steven Patierno, PhD
Kevin C. Oeffinger, MD
Kevin Shah, MD, MBA
Publication date
01-01-2021
Publisher
Springer International Publishing
Published in
Journal of General Internal Medicine / Issue 1/2021
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-020-06124-2

Other articles of this Issue 1/2021

Journal of General Internal Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.